Literature DB >> 8508820

Cefotiam concentrations in the sinus fluid of patients with chronic sinusitis after administration of cefotiam hexetil.

P Cherrier1, M Tod, V Le Gros, O Petitjean, N Brion, A Chatelin.   

Abstract

Cefotiam hexetil is a prodrug of cefotiam. The concentrations of cefotiam in plasma and sinus secretions were determined in 18 patients (10 males, 8 females, aged 39.3 +/- 13.0 years) with chronic sinusitis. All patients received two 200 mg oral doses of cefotiam hexetil 12 h apart and were divided into four groups according to the time which elapsed between the last dose and collection of secretion samples. The last dose was given 2 h (group I), 3 h (group II), 4 h (group III) or 6 h (group IV) before sinus puncture. Cefotiam concentrations were measured by high-pressure liquid chromatography and microbiological assay, results being very similar with both methods. Mean concentrations of cefotiam with the standard deviation in sinus exudates were 1.04 +/- 0.60 mg/l at 2 h (n = 6), 1.04 +/- 0.33 mg/l at 3 h (n = 4), 0.75 +/- 0.74 mg/l at 4 h (n = 4) and < 0.10 mg/l at 6 h (n = 4). Mean sinus fluid concentrations were higher than mean plasma concentrations in all groups. These results suggest that cefotiam concentrations higher than the MICs for common pathogens are found in sinus secretions up to 4 h after oral administration of cefotiam hexetil.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8508820     DOI: 10.1007/BF01967115

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN: 0934-9723            Impact factor:   3.267


  5 in total

1.  The blood binding of cefotiam and cyclohexanol, metabolites of the prodrug cefotiam hexetil, in-vitro.

Authors:  V Querol-Ferrer; R Zini; J P Tillement
Journal:  J Pharm Pharmacol       Date:  1991-12       Impact factor: 3.765

2.  High-performance liquid chromatographic assay for cefotiam and d3-cefotiam in human serum.

Authors:  F Kees; W Raasch; M Steger; H Grobecker
Journal:  J Chromatogr       Date:  1990-02-23

3.  [Cefotiam passage into the maxillary sinus tissues].

Authors:  M Nakashima; H Ikoma; M Yokoyama; T Suzuki; S Sugihara
Journal:  Jpn J Antibiot       Date:  1983-10

4.  [Transport of cefotetan into the otorhinolaryngeal tissues].

Authors:  Y Fujimaki; S Kawamura; R Sugita
Journal:  Jpn J Antibiot       Date:  1983-06

5.  [Diffusion of piperacillin into the sinuses of patients with nosocomial sinusitis].

Authors:  L Holzapfel; F Jehl; P Miranda; F Lyonnet; A Coupry; G Demingeon; D Carrère-Debat
Journal:  Presse Med       Date:  1991-11-16       Impact factor: 1.228

  5 in total
  1 in total

Review 1.  Clinical pharmacokinetics of newer cephalosporins.

Authors:  M E Klepser; M N Marangos; K B Patel; D P Nicolau; R Quintiliani; C H Nightingale
Journal:  Clin Pharmacokinet       Date:  1995-05       Impact factor: 6.447

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.